

ABSTRACT TEMPLATE for Company Presentations

Answers should not exceed 60 words per question

- **Investment Rational**

Matricelf is an Israeli publicly traded (TASE:MTLF) biotechnology company in the field of regenerative medicine and tissue engineering.

The company develops a platform of autologous 3D tissues and organs that significantly reduces the risk of implant rejection.

Using the patient own cells and extracellular matrix we develop tissues for a variety of medical conditions.

- **Business Strategy**

Our first “go to clinical” indication is spinal cord injury (SCI).

In our pre-clinical animal studies, mice treated with 3D neural implants regained their walking ability both in acute and chronic spinal cord injury models.

We are planning to establish regional excellence centers in which the 3D tissues will be produced and the surgical procedure will be performed.

- **Core Technology**

Matricelf's technology enables the production of autologous engineered tissues. In which both cells and extracellular matrix are derived from the same patient

The matrix is omentum-derived and the induced pluripotent stem cells (iPSCs) are blood-derived.

Ex vivo differentiation of iPSCs within hydrogel (matrix) leads to the generation of neural tissue implants

- **Product Profile/Pipeline**

Our platform technology enables the production of a variety of tissues.

We are focused on SCI and have established several global partnerships that support the development our technology.

There are thousands of paralyzed patients due to SCI; a medical condition that has a huge economic, social and medical burden

- **What's Next?**

We are preparing for efficacy and safety studies aiming for a first human clinical trial in 2024 (The RD program presented to the FDA as part of pre-IND meeting).

We are planning to expand our R&D facility to include clean rooms for GMP manufacturing and launch a 2nd indication.

The company is fully funded for the next 18 months.